BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 22928581)

  • 1. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays.
    Vande Casteele N; Buurman DJ; Sturkenboom MG; Kleibeuker JH; Vermeire S; Rispens T; van der Kleij D; Gils A; Dijkstra G
    Aliment Pharmacol Ther; 2012 Oct; 36(8):765-71. PubMed ID: 22928581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.
    Wang SL; Ohrmund L; Hauenstein S; Salbato J; Reddy R; Monk P; Lockton S; Ling N; Singh S
    J Immunol Methods; 2012 Aug; 382(1-2):177-88. PubMed ID: 22691619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.
    Ben-Horin S; Yavzori M; Katz L; Kopylov U; Picard O; Fudim E; Coscas D; Bar-Meir S; Goldstein I; Chowers Y
    Gut; 2011 Jan; 60(1):41-8. PubMed ID: 20519742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease.
    Imaeda H; Andoh A; Fujiyama Y
    J Gastroenterol; 2012 Feb; 47(2):136-43. PubMed ID: 21953314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
    Marini JC; Sendecki J; Cornillie F; Popp JW; Black S; Blank M; Gils A; Van Stappen T; Hamann D; Rispens T; Thérien L; Chun K; Shankar G
    AAPS J; 2017 Jan; 19(1):161-171. PubMed ID: 27600137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.
    Ungar B; Chowers Y; Yavzori M; Picard O; Fudim E; Har-Noy O; Kopylov U; Eliakim R; Ben-Horin S;
    Gut; 2014 Aug; 63(8):1258-64. PubMed ID: 24041539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of low level infliximab in the absence of anti-infliximab antibodies.
    Ungar B; Anafy A; Yanai H; Ron Y; Yavzori M; Picard O; Fudim E; Loebstein R; Kopylov U; Chowers Y; Dotan I; Eliakim R; Ben-Horin S
    World J Gastroenterol; 2015 Feb; 21(6):1907-14. PubMed ID: 25684959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
    Nasser Y; Labetoulle R; Harzallah I; Berger AE; Roblin X; Paul S
    Dig Dis Sci; 2018 Oct; 63(10):2714-2721. PubMed ID: 29948562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody response to infliximab and its impact on pharmacokinetics can be transient.
    Vande Casteele N; Gils A; Singh S; Ohrmund L; Hauenstein S; Rutgeerts P; Vermeire S
    Am J Gastroenterol; 2013 Jun; 108(6):962-71. PubMed ID: 23419382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.
    Plasencia C; Pascual-Salcedo D; Nuño L; Bonilla G; Villalba A; Peiteado D; Díez J; Nagore D; del Agua AR; Moral R; Martin-Mola E; Balsa A
    Ann Rheum Dis; 2012 Dec; 71(12):1955-60. PubMed ID: 22563028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases.
    Van Stappen T; Billiet T; Vande Casteele N; Compernolle G; Brouwers E; Vermeire S; Gils A
    Inflamm Bowel Dis; 2015 Sep; 21(9):2172-7. PubMed ID: 26284296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.
    Farrell RJ; Alsahli M; Jeen YT; Falchuk KR; Peppercorn MA; Michetti P
    Gastroenterology; 2003 Apr; 124(4):917-24. PubMed ID: 12671888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study.
    Adişen E; Aral A; Aybay C; Gürer MA
    J Dermatol; 2010 Aug; 37(8):708-13. PubMed ID: 20649712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter: detection of infliximab levels and anti-infliximab antibodies--comparison of three different assays.
    Parussini E
    Aliment Pharmacol Ther; 2013 Jan; 37(2):281. PubMed ID: 23252782
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter: detection of infliximab levels and anti-infliximab antibodies--comparison of three different assays; authors' reply.
    Buurman DJ; Vande Casteele N; Sturkenboom MG; Kleibeuker JH; Vermeire S; van der Kleij D; Rispens T; Gils A; Dijkstra G
    Aliment Pharmacol Ther; 2013 Jan; 37(2):282. PubMed ID: 23252783
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of Immunoassays for Measuring Serum Levels of Golimumab and Antibodies Against Golimumab in Ulcerative Colitis: A Retrospective Observational Study.
    Berger AE; Duru G; de Vries A; Marini JC; Aoucheta D; Cornillie F; Nancey S; Detrez I; Gils A; Roblin X; Paul S
    Ther Drug Monit; 2019 Aug; 41(4):459-466. PubMed ID: 30817702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of three commercially available ELISA assays for anti-infliximab antibodies.
    West TA; Sam M; Toong C
    Pathology; 2021 Jun; 53(4):508-514. PubMed ID: 33272693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.
    Kopylov U; Mazor Y; Yavzori M; Fudim E; Katz L; Coscas D; Picard O; Chowers Y; Eliakim R; Ben-Horin S
    Inflamm Bowel Dis; 2012 Sep; 18(9):1628-33. PubMed ID: 22038899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of infliximab drug measurement across three commercially available ELISA kits.
    Lee MW; Connor S; Ng W; Toong CM
    Pathology; 2016 Oct; 48(6):608-12. PubMed ID: 27567230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure.
    Ungar B; Haj-Natour O; Kopylov U; Yavzori M; Fudim E; Picard O; Loebstein R; Lahat A; Maor Y; Avidan B; Lang A; Weiss B; Chowers Y; Eliakim R; Ben-Horin S
    Medicine (Baltimore); 2015 May; 94(18):e673. PubMed ID: 25950682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.